YUMAB and InSCREENeX in search of new targets and compounds against pancreatic cancer
Companies work together on innovative approaches to individual tumor research in exPDITE funding project
YUMAB GmbH, a German biotechnology company specializing in contract research of therapeutic antibodies, announces its collaboration with InSCREENeX GmbH under the "exPDITE" funding project. The goal of the collaboration is to enable improved drug development for the individual treatment of patients with pancreatic cancer. To this end, patient-specific tissues will be propagated in the laboratory using InSCREENeX's CI-SCREEN technology to identify new tumor targets using YUMAB's proprietary antibody databases.
In the BMBF-funded exPDITE project, InSCREENeX and YUMAB are searching for new target molecules in individual tissues of tumor patients for improved drug development.
© InSCREENeX GmbH
The "exPDITE" research project, which is budgeted at 1.8 million euros, is supported by the German Federal Ministry of Education and Research (BMBF) with 1.1 million euros until 2026.
In the search for the answer as to how healthy tissues differ from pancreatic tumor tissues at the individual patient level, exPDITE is pursuing a completely new approach. Tumor samples are propagated together with tumor-associated and healthy tissues from the same patient in the laboratory in a way that preserves the original properties of the respective starting tissue. InSCREENeX has developed and patented CI-SCREEN, a technology that is designed to do just that.
Using the in vitro-expanded individual tissues and cells(expanded patient-derived tumors, exPDT) and the company's own human antibody libraries, YUMAB will search for new drug candidates against previously unknown target structures that selectively recognize diseased cells but not healthy tissue. The new targets thus identified and new, more realistic in vitro model systems are expected to improve drug development.
YUMAB Managing Director Dr. Thomas Schirrmann is pleased about the BMBF funding for the project: "With this funding, we can combine the unique technologies of the two research companies in Braunschweig to gain a better biological understanding of solid tumor diseases, such as pancreatic cancer, and at the same time open the door for the development of new drugs."
Dr. Roland Schucht, CEO of InSCREENeX GmbH, also welcomes the funded cooperation: "The bundling of our competencies in the exPDITE project is a prime example of the use of synergies in the translation of research into drug development at the Braunschweig site."
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
